Adma Biologics (ADMA) Inventory Average (2012 - 2025)

Adma Biologics has reported Inventory Average for 11 years, with the latest figure at $201.6 million in Q4 2025.

• For the quarter ending Q4 2025, Inventory Average rose 17.86% year-over-year to $201.6 million; the trailing twelve-month figure through Dec 2025 stood at $201.6 million (up 17.86% YoY), and the FY2025 full-year result was $188.4 million, up 9.78% from the prior year.
• Inventory Average for Q4 2025 stood at $201.6 million, up from $194.1 million in the prior quarter.
• The five-year high for Inventory Average was $201.6 million in Q4 2025, with the low at $87.8 million in Q1 2021.
• Historically, Inventory Average has averaged $155.5 million across 5 years, with a median of $163.4 million in 2022.
• Annual changes were most pronounced in 2021 — Inventory Average jumped 66.75% — and 2025, when it decreased 2.34%.
• Adma Biologics' Inventory Average stood at $119.4 million in 2021, then jumped by 36.57% to $163.1 million in 2022, then increased by 3.01% to $168.0 million in 2023, then grew by 1.79% to $171.0 million in 2024, then advanced by 17.86% to $201.6 million in 2025.
• The last three Inventory Average figures came in at $201.6 million (Q4 2025), $194.1 million (Q3 2025), and $181.8 million (Q2 2025), per Business Quant data.